X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs TORRENT PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES TORRENT PHARMA PIRAMAL ENTERPRISES/
TORRENT PHARMA
 
P/E (TTM) x 8.9 36.9 24.1% View Chart
P/BV x 2.9 5.7 51.2% View Chart
Dividend Yield % 0.8 0.9 87.3%  

Financials

 PIRAMAL ENTERPRISES   TORRENT PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
TORRENT PHARMA
Mar-17
PIRAMAL ENTERPRISES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2,0951,768 118.5%   
Low Rs1,0251,186 86.5%   
Sales per share (Unadj.) Rs492.8346.1 142.4%  
Earnings per share (Unadj.) Rs72.655.2 131.5%  
Cash flow per share (Unadj.) Rs94.773.3 129.2%  
Dividends per share (Unadj.) Rs21.0014.00 150.0%  
Dividend yield (eoy) %1.30.9 142.0%  
Book value per share (Unadj.) Rs862.5257.1 335.5%  
Shares outstanding (eoy) m172.56169.22 102.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.24.3 74.2%   
Avg P/E ratio x21.526.8 80.3%  
P/CF ratio (eoy) x16.520.1 81.8%  
Price / Book Value ratio x1.85.7 31.5%  
Dividend payout %28.925.4 114.1%   
Avg Mkt Cap Rs m269,194249,887 107.7%   
No. of employees `0004.011.8 34.1%   
Total wages/salary Rs m17,9399,934 180.6%   
Avg. sales/employee Rs Th21,190.34,971.5 426.2%   
Avg. wages/employee Rs Th4,470.1843.2 530.1%   
Avg. net profit/employee Rs Th3,120.0792.4 393.7%   
INCOME DATA
Net Sales Rs m85,03758,569 145.2%  
Other income Rs m2,3382,233 104.7%   
Total revenues Rs m87,37460,802 143.7%   
Gross profit Rs m34,99113,773 254.1%  
Depreciation Rs m3,8173,069 124.4%   
Interest Rs m20,3102,056 988.0%   
Profit before tax Rs m13,20210,881 121.3%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2811,545 147.6%   
Profit after tax Rs m12,5209,336 134.1%  
Gross profit margin %41.123.5 175.0%  
Effective tax rate %17.314.2 121.7%   
Net profit margin %14.715.9 92.4%  
BALANCE SHEET DATA
Current assets Rs m87,59053,841 162.7%   
Current liabilities Rs m185,57831,612 587.1%   
Net working cap to sales %-115.238.0 -303.6%  
Current ratio x0.51.7 27.7%  
Inventory Days Days3197 31.9%  
Debtors Days Days4884 56.8%  
Net fixed assets Rs m108,52342,079 257.9%   
Share capital Rs m345846 40.8%   
"Free" reserves Rs m148,48142,655 348.1%   
Net worth Rs m148,82643,501 342.1%   
Long term debt Rs m144,95722,408 646.9%   
Total assets Rs m482,394101,250 476.4%  
Interest coverage x1.76.3 26.2%   
Debt to equity ratio x1.00.5 189.1%  
Sales to assets ratio x0.20.6 30.5%   
Return on assets %6.811.3 60.5%  
Return on equity %8.421.5 39.2%  
Return on capital %12.019.6 60.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00120,066 74.8%   
Fx outflow Rs m5,1505,304 97.1%   
Net fx Rs m9,85114,762 66.7%   
CASH FLOW
From Operations Rs m-100,39310,127 -991.3%  
From Investments Rs m-24,202-7,869 307.6%  
From Financial Activity Rs m135,705-1,918 -7,075.3%  
Net Cashflow Rs m11,110212 5,252.8%  

Share Holding

Indian Promoters % 52.9 71.5 74.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 7.0 57.0%  
FIIs % 26.6 12.6 211.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.8 187.5%  
Shareholders   93,274 26,511 351.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FULFORD INDIA  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 21, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS